AGENDA DAY 1

 

Microbiome World Congress USA Day 1 2017

8:50 Chairperson’s Opening Remarks

TURNING RESEARCH INTO VIABLE THERAPEUTICS

09:00

Keynote Address: The new paradigm of treatment: Understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

  • What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
  • When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
  • What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?
09:20

Keynote address: Finding the fundamental Principles of the Microbiome

  • What about the human microbiome can be understood from bacterial interactions we see in plants, animals, and the environment?
  • How does Multi-scale modelling enable us to investigate the emergent ecological properties stemming from interactions among microbes and their interactions with the environment?
  • From these relationships what evidence have we seen in regards to common and fundamental principle so far? What interactions can be ignored?
  • How do we delineate these understandings to identify translational impacts for altering existing properties and ultimately human health?
09:20

Keynote address: Finding the fundamental Principles of the Microbiome

  • What about the human microbiome can be understood from bacterial interactions we see in plants, animals, and the environment?
  • How does Multi-scale modelling enable us to investigate the emergent ecological properties stemming from interactions among microbes and their interactions with the environment?
  • From these relationships what evidence have we seen in regards to common and fundamental principle so far? What interactions can be ignored?
  • How do we delineate these understandings to identify translational impacts for altering existing properties and ultimately human health?
09:40

9:40 Title Sponsor Session

10:00

10:00 Speed Networking

10:20 Networking coffee break

INFECTIONS AND ANTIBIOTICS

CLINICAL TRIAL DESIGN, DATA AND PATIENT RECRUITMENT

FUNDING

Scientific
11:00

Presentation: Re-assessing ethical issues in Microbiome research and medicine

  • What implications does Microbiome Research have on our social and legal systems?
  • Studies to advance personalized medicine will require broad public participation to provide sufficient material for biobanks and sample banks rather than a small sample of people with a target condition. 
  • How does this change the focus from the individual to community solidarity?
Commercial
11:00

FDA update: points to consider in when developing Microbiome treatments

  • Challenges in developing microbial treatments
  • Regulatory implications of C. Difficile- microbiome- Host interactions.
  • Understanding current guidelines for living biological samples.
Pitch & Partner
11:00

Funding Case Study I

Scientific
11:20

Presentation: The Hygiene Hypothesis and Lessons learned from Drug Development

  • How can we fight years of ingrained antibacterial habits?
  • How do we identify and address the underlying causes of inflammation in Western society?
  • What potential do we see in the field of microbiome?
  • What evidence have we seen of positive immune health from early introduction to rich microbiotas from pets, to environmental. etc?
Commercial
11:20

Presentation: Disparity of Minority representation in Clinical Trials

  • With the Microbiome field, so young it is important to push for diverse trials.
  • What microbial differences are we seeing across cultures and races?
  • How can these differences inform treatments for all people?
  • How do you engage underserved groups at the community level to build trust in access to cutting edge trials?
Pitch & Partner
11:20

Funding Case Study II

Scientific
11:40

Presentation: Developing novel antibiotic therapies that do not destroy the healthy microbiome

  • Is long term and aggressive use of antibiotics bringing our microflora to a point of no return?
  • What are “Eligobiotics” and How can we identify and develop antimicrobials of such Precision?
  • What needs to be done to create more antimicrobial treatments that don’t harm our healthy microbial makeup?
Commercial
11:40

Presentation: Clinical innovations in Microbiome: From wellness to treatment

  • The proper regulation of Microbiome is essential if the field is to be taken seriously as a viable treatment for diseases.
  • How do we move away from the wild west like scene of dietary supplements?
  • What can we learn from recent partnerships and breakthroughs?
Scientific
11:50

Sponsored case study

Commercial
11:50

Sponsored case study

12:00 ROUNDTABLES

Roundtable 1: Mouse Models: The great potential and limitations of the mouse model

Roundtable 2: Loss of Food Species: How is a reduction in Dietary diversity affecting our Microbiome?

Jose Clemente

Roundtable 3: Pre-Antibiotic Cultures: What can we learn from the gut diversity of the Amerindians?

Paul Carlson

Roundtable 5: ) FMT Regulation: Identifying and understanding best practices

Paul Carlson, Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, F.D.A.

Roundtable 6: Caesarean Delivery: How do we enhance newborn microbiota with vaginal microbiota of the mother?

Roundtable 7: Ethics Issues: Biobanking and the microbiome – use and applications

Roundtable 9:Machine Learning: Training computers to understand our gut

12:40 LUNCH

BRAIN

DRUG DEVELOPMENT- BIOMARKER

PITCH

Scientific
14:00

Keynote address: The human gut mycobiome: pitfalls and potentials

  • Every human has fungi as part of their microbiota, but the total number of fungal cells is orders of magnitude smaller than that of the bacterial microbiota. Why is the Fungal Microbiome or “Mycobiome” so important yet constantly overlooked?
  • The impact of the mycobiome on human health is significant, especially as a reservoir for blooms of pathogenic microbes when the host is compromised and as a potential cofactor in inflammatory diseases and metabolic disorders.
  • How are advances high-throughput sequencing and bioinformatics beginning to reveal the breadth, depth, and diversity of the fungal world in humans and throughout the environment?
Commercial
14:00

Presentation: Developments of Targeted Therapy via Microbiome Community

  • The level of uniqueness in the microbiome make up means far more
  • How can we enhance sampling protocols with high quality metagenomic data?
  • How in depth must we go to identify key bacteria of interest?
  • With current treatments having wide ranging responses in patients- How personalized does each treatment need to be?
Scientific
14:20

Presentation: Finding a functional link between Parkinson’s and the Gut Microbiome

  • What microbes are missing in patients with PD?
  • Would the presence of these normally prevent Parkinson’s?
  • Can early GI detection of imbalance of SCFA’s help diagnose in the early stages?
Commercial
14:20

Panel: Addressing the inherent challenges in Bioinformatics

  • Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
  • How do we continue to identify the stable sub communities?
  • What bacterial interactions can we look to outside of our immediate field?
Scientific
14:40

Presentation: The Microbiome and Multiple Sclerosis

  • How can the Gut Microbiome shape host immunity and communicate with CNS via Gut Brain Axis?
  • What microbes, genes and metabolites have been identified that protect from autoimmunity?
  • How does the gut microbiome affect treatment efficiency of MS drugs in Mouse models?
Scientific
14:50

Sponsored case study

Commercial
14:50

Presentation: How precisely targeted drugs are changing the behaviour of the microbiome

  • With the billions of possible microbes the task of identifying and verifying a positive lead is key to effective drug development.
  • With bacterial communities being so specific to regions how do we optimize best combinations?
  • How can we take advantage of Syntheitic Biologics to enhance and encourage healthy interactions?

OBESITY AND CANCER

DRUG DEVELOPMENT- DIAGNOSTIC VALIDATION

PITCH

Scientific
15:00

Presentation: A healthy gastrointestinal microbiome is dependent on dietary diversity

  • How has a push for food production led to a dearth of food species?
  • How does this lack of diversity negatively impact a rich microbiome?
  • With the gut microbiome able to evolve so rapidly- How can we use food to influence it?
Commercial
15:00

Case Study: Gut-on-a-Chip, changing the future of PV for the Microbiome

  • A microphysiological human intestine model
  • In vitro host-gut microbiome ecosystem and long-term maintenance
  • Modeling intestinal diseases to validate therapeutic interventions
Scientific
15:20

Panel: The extreme personalization potential in Microbiome and Immunotherapy

  • How are the trillions of bacteria in our bodies creating unique individual makeups?
  • Are drug immunotherapies reacting to the microflora of our gut?
  • What promising efforts have been made to align with immunotherapy?
Commercial
15:20

Presentation: Teaching Computers to recognize the sick gut

  • What advantages do Machine learning offer us in Microbiome?
  • How do you train systems to identify Healthy bacteria communities?
  • What relationships are we looking for as we are rarely looking at just one molecule?
Commercial
15:40

Presentation: Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes

  • Presenting an integrative approach to resolve the taxonomic and functional attributes of GI microbiota at the metagenomic, metatranscriptomic and metaproteomic levels.
  • What influence does family membership have on Gut make up?
  • What do these findings mean for future large-scale integrated multi-omic analyses of the GI microbiome in the context of host-microbe interactions?
Scientific
15:50

Presentation: The Metagenomic and Metadesign of Subways and Urban Biomes

  • How can we improve city utilization and planning through the detection, measurement, and design of metagenomics within urban environments?
  • How can these baseline profiles be used to identify potential bio-threats, and provide an additional level of data, that can even aid in Smart City Capabilities?
Commercial
15:50

Sponsored case study

16:00 Networking coffee break

Closing keynotes

16:40

Keynote Panel: Strategic partnerships to rapidly advance microbiome treatments

  • How are small and lean Biotechs’ defining new pathways for products?
  • How do we drive the field forward by collaborating with leading academics and entrepreneurs to generate and advance novel health solutions?
  • The payoff for being first-to-market with a successful microbiome-based therapy could be as large as that of blockbuster drugs of the past.
  • How do you identify the most effective partnerships without falling into fads?
17:00

Keynote: Unlocking Human Potential with the Human Microbiome Project

  • How is the HMP enabling the comprehensive characterization of the human microbiome and analysis of its role in human health and disease?
  • Has the microbiota evolved ways to benefit itself and its host by influencing human behavior? 
  • How is this global and interdisciplinary project breaking down the artificial barriers between medical and environmental microbiology?

17:20 Closing Remarks

17:30 Drinks Reception

last published: 30/May/17 19:05 GMT